TW200637565A - Use of a sterically hindered platium coordination compound in combination with a non-platium based anti-cancer agent - Google Patents

Use of a sterically hindered platium coordination compound in combination with a non-platium based anti-cancer agent

Info

Publication number: TW200637565A
Authority: TW; Taiwan
Prior art keywords: platium; sterically hindered; cancer agent; coordination compound; based anti
Prior art date: 2000-05-18

Application number

TW095125500A

Other languages

English (en)

Inventor

Mark Peart Smith

Trevor Charles Stephens

Original Assignee

Anormed Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-18

Filing date

2001-05-21

Publication date

2006-11-01

2001-05-21 Application filed by Anormed Inc filed Critical Anormed Inc

2006-11-01 Publication of TW200637565A publication Critical patent/TW200637565A/zh

Links

239000002246 antineoplastic agent Substances 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 title abstract 3
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 8
229910052697 platinum Inorganic materials 0.000 abstract 4
230000002401 inhibitory effect Effects 0.000 abstract 3
210000004881 tumor cell Anatomy 0.000 abstract 3
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 abstract 2
239000013066 combination product Substances 0.000 abstract 2
229940127555 combination product Drugs 0.000 abstract 2
230000012010 growth Effects 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
229940115080 doxil Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
229960002949 fluorouracil Drugs 0.000 abstract 1
229960005277 gemcitabine Drugs 0.000 abstract 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229940086322 navelbine Drugs 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
125000002456 taxol group Chemical group 0.000 abstract 1
229940063683 taxotere Drugs 0.000 abstract 1
CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Inorganic Chemistry (AREA)
Optics & Photonics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW095125500A 2000-05-18 2001-05-21 Use of a sterically hindered platium coordination compound in combination with a non-platium based anti-cancer agent TW200637565A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0011903.2A GB0011903D0 (en)	2000-05-18	2000-05-18	Combination chemotherapy

Publications (1)

Publication Number	Publication Date
TW200637565A true TW200637565A (en)	2006-11-01

Family

ID=9891766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095125500A TW200637565A (en)	2000-05-18	2001-05-21	Use of a sterically hindered platium coordination compound in combination with a non-platium based anti-cancer agent

Country Status (28)

Country	Link
US (1)	US20040053882A1 (zh)
EP (2)	EP1283712A1 (zh)
JP (2)	JP2003533485A (zh)
KR (2)	KR20030014228A (zh)
CN (3)	CN101310719A (zh)
AR (1)	AR030281A1 (zh)
AU (3)	AU2001252442B8 (zh)
BG (1)	BG66113B1 (zh)
BR (1)	BR0110837A (zh)
CA (1)	CA2410067A1 (zh)
CZ (1)	CZ20023766A3 (zh)
EE (1)	EE05261B1 (zh)
GB (1)	GB0011903D0 (zh)
HK (1)	HK1049446A1 (zh)
HU (1)	HUP0302130A3 (zh)
IL (1)	IL151959A0 (zh)
IS (1)	IS6571A (zh)
MX (1)	MXPA02011247A (zh)
MY (1)	MY138923A (zh)
NO (1)	NO332079B1 (zh)
NZ (1)	NZ521632A (zh)
PL (1)	PL357721A1 (zh)
RU (2)	RU2429838C2 (zh)
SK (1)	SK16392002A3 (zh)
TW (1)	TW200637565A (zh)
UA (1)	UA81098C2 (zh)
WO (1)	WO2001087313A1 (zh)
ZA (1)	ZA200209279B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US8791081B2 (en) *	1999-08-13	2014-07-29	Case Western Reserve University	MGMT inhibitor combination for the treatment of neoplastic disorders
MEP36208A (en) *	2001-12-03	2011-02-10	Bayer Corp	Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
WO2004087105A1 (en) *	2003-04-02	2004-10-14	Celator Pharmaceuticals, Inc.	Combination formulations of platinum agents and fluoropyrimidines
RU2273475C2 (ru) *	2004-04-06	2006-04-10	Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ)	Способ лечения диссеминированного колоректального рака
ES2392544T3 (es) *	2005-06-07	2012-12-11	Yale University	Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT
US7616481B2 (en) *	2005-12-28	2009-11-10	Sandisk Corporation	Memories with alternate sensing techniques
EP2094268A2 (en) *	2006-05-26	2009-09-02	Bayer HealthCare, LLC	Drug combinations with substituted diaryl ureas for the treatment of cancer
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
RU2340336C1 (ru) *	2007-05-02	2008-12-10	Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН)	Способ комбинированного лечения немелкоклеточного рака легкого iii стадии
US20100260832A1 (en) *	2007-06-27	2010-10-14	Poniard Pharmaceuticals, Inc.	Combination therapy for ovarian cancer
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20100310661A1 (en) *	2007-07-16	2010-12-09	Poniard Pharmaceuticals, Inc.	Oral formulations for picoplatin
US20110053879A1 (en) *	2008-02-08	2011-03-03	Poniard Pharmaceuticals, Inc.	Picoplatin and amrubicin to treat lung cancer
CN101302235B (zh) *	2008-06-30	2011-06-01	昆明贵研药业有限公司	甲啶铂的提纯
US20130211384A1 (en) *	2010-07-28	2013-08-15	Fondazione Irccs Istituto Nazionale Dei Tumori	Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
KR101389072B1 (ko) *	2011-05-25	2014-04-23	가톨릭대학교 산학협력단	ＢＨＲＦ１ 발현 억제를 위한 ｓｉＲＮＡ 및 이를 포함하는 조성물
WO2017060661A1 (en) *	2015-10-05	2017-04-13	Nucana Biomed Limited	Combination therapy
HUE063275T2 (hu)	2017-05-16	2024-01-28	Ability Pharmaceuticals S A	Gyógyszerészeti kombináció rákbetegség kezelésére
CN113694205B (zh) *	2021-09-23	2023-05-16	山东第一医科大学(山东省医学科学院)	5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1432562A (en) *	1972-04-10	1976-04-22	Rustenburg Platinum Mines Ltd	Platinum co-ordination compounds
ZA805101B (en) *	1979-08-23	1981-08-26	Johnson Matthey Co Ltd	Compositions containing platinium
US4302446A (en) *	1979-10-02	1981-11-24	Bristol-Myers Company	Pharmaceutical compositions
IL63658A0 (en) *	1980-09-03	1981-11-30	Johnson Matthey Plc	Co-ordination compound of platinum and its preparation
US4533502A (en) *	1983-02-22	1985-08-06	Rochon Fernande D	Platinum (II) compounds and their preparation
EP0167310B1 (en) *	1984-06-27	1991-05-29	Johnson Matthey Public Limited Company	Platinum co-ordination compounds
US5082655A (en) *	1984-07-23	1992-01-21	Zetachron, Inc.	Pharmaceutical composition for drugs subject to supercooling
FR2586428B1 (fr) *	1985-08-26	1988-11-25	Pasteur Institut	Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
CA1327039C (en) *	1986-12-18	1994-02-15	Tetsushi Totani	Ammine-alicyclic amine-platinum complexes and antitumor agents
MX9203808A (es) *	1987-03-05	1992-07-01	Liposome Co Inc	Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CN1016693B (zh) *	1987-06-05	1992-05-20	北京工业大学	新顺铂铬合物的制备方法
GB9105037D0 (en) *	1991-03-09	1991-04-24	Johnson Matthey Plc	Improvements in chemical compounds
US5244991A (en) *	1991-10-15	1993-09-14	Phillips Petroleum Company	Olefin polymerization process
WO1993009782A1 (en) *	1991-11-15	1993-05-27	Smithkline Beecham Corporation	Combination chemotherapy
CA2132874C (en) *	1992-04-01	2003-08-19	Bert Vogelstein	Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
FR2707988B1 (fr) *	1993-07-21	1995-10-13	Pf Medicament	Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
US5624919A (en) *	1993-09-14	1997-04-29	The University Of Vermont And State Agricultural College	Trans platinum (IV) complexes
GB9408218D0 (en) *	1994-04-26	1994-06-15	Johnson Matthey Plc	Improvements in platinum complexes
WO1996001638A1 (en) *	1994-07-11	1996-01-25	Hoechst Marion Roussel, Inc.	Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5626862A (en) *	1994-08-02	1997-05-06	Massachusetts Institute Of Technology	Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1039813C (zh) *	1994-10-31	1998-09-16	西安五环(集团)股份有限公司	具抗癌效应的顺式-二氨-1,1-环戊二羧酸根合铂(ⅱ)的化合物及其合成方法
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) *	1994-11-14	1998-08-04	Bionumerik Pharmaceuticals, Inc.	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
GB9502799D0 (en) *	1995-02-14	1995-04-05	Johnson Matthey Plc	Improvements in platinum complexes
CN1039588C (zh) *	1995-03-29	1998-08-26	邹娟	新的抗肿瘤铂络合物
US6245349B1 (en) *	1996-02-23	2001-06-12	éLAN CORPORATION PLC	Drug delivery compositions suitable for intravenous injection
US6441025B2 (en) *	1996-03-12	2002-08-27	Pg-Txl Company, L.P.	Water soluble paclitaxel derivatives
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
JP2000515852A (ja) *	1996-06-25	2000-11-28	グラクソ、グループ、リミテッド	Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
EA002594B1 (ru) *	1997-02-03	2002-06-27	Пфайзер Продактс Инк.	Производные арилсульфониламиногидроксамовой кислоты
AU3961899A (en) *	1998-05-04	1999-11-23	Auckland Uniservices Limited	Chemotherapeutic treatment
DE19847618A1 (de) *	1998-10-15	2000-04-20	Basf Ag	Verfahren zur Herstellung von festen Dosierungsformen
US6235782B1 (en) *	1998-11-12	2001-05-22	Rifat Pamukcu	Method for treating a patient with neoplasia by treatment with a platinum coordination complex
US6413953B1 (en) *	1999-04-13	2002-07-02	Anormed Inc.	Pt(IV) antitumor agent
MXPA01010430A (es) *	1999-04-13	2002-03-27	Anormed Inc	Procedimiento para preparar complejos de aminoplatino.
CA2386476A1 (en) *	1999-10-18	2001-04-26	Emory University	Tms1 compositions and methods of use
GB9925127D0 (en) *	1999-10-22	1999-12-22	Pharmacia & Upjohn Spa	Oral formulations for anti-tumor compounds
US20020102301A1 (en) *	2000-01-13	2002-08-01	Joseph Schwarz	Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6420473B1 (en) *	2000-02-10	2002-07-16	Bpsi Holdings, Inc.	Acrylic enteric coating compositions
EP1256344B1 (en) *	2000-02-16	2006-12-20	Astellas Pharma Inc.	Remedies for endothelin-induced diseases
JP2003525246A (ja) *	2000-02-29	2003-08-26	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US6545010B2 (en) *	2000-03-17	2003-04-08	Aventis Pharma S.A.	Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US20020110601A1 (en) *	2000-03-31	2002-08-15	Roman Perez-Soler	Antineoplastic platinum therapeutic method and composition
EE200200565A (et) *	2000-03-31	2004-06-15	Angiogene Pharmaceuticals Ltd.	Vaskulaarse kahjustava toimega kombinatsioonravi
AU2001277711A1 (en) *	2000-08-11	2002-02-25	Sumitomo Pharmaceuticals Co. Ltd.	Remedies for cisplatin-tolerant cancer
US6894049B1 (en) *	2000-10-04	2005-05-17	Anormed, Inc.	Platinum complexes as antitumor agents
CA2326004A1 (en) *	2000-11-02	2002-05-02	Richard E. Jones	Methods for treating cellular proliferative disorders
SE0004671D0 (sv) *	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
US6673370B2 (en) *	2001-05-15	2004-01-06	Biomedicines, Inc.	Oxidized collagen formulations for use with non-compatible pharmaceutical agents
NZ530916A (en) *	2001-08-06	2005-07-29	Astrazeneca Ab	Stable dispersions of solid particles in an aqueous medium prepared without need for water-immiscible solvents for formation of the emulsion
WO2003015707A2 (en) *	2001-08-20	2003-02-27	Transave, Inc.	Method for treating lung cancers
DE10141528B4 (de) *	2001-08-24	2006-08-10	Faustus Forschungs Cie. Translational Cancer Research Gmbh	Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
US6669955B2 (en) *	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030144312A1 (en) *	2001-10-30	2003-07-31	Schoenhard Grant L.	Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003057128A2 (en) *	2001-12-11	2003-07-17	Dor Biopharma, Inc.	Lipid particles and suspensions and uses thereof
WO2003074006A2 (en) *	2002-03-01	2003-09-12	Trustees Of Dartmouth College	Compositions and methods for preventing sporadic neoplasia in colon
US20040010553A1 (en) *	2002-07-15	2004-01-15	International Business Machines Corporation	Peer to peer location based services
AU2003251955A1 (en) *	2002-07-16	2004-02-02	Sonus Pharmaceuticals, Inc.	Platinum compound
CA2494673A1 (en) *	2002-08-02	2004-07-01	Transave, Inc.	Platinum aggregates and process for producing the same
AU2003258075A1 (en) *	2002-08-06	2004-02-23	Lyotropic Therapeutics, Inc.	Lipid-drug complexes in reversed liquid and liquid crystalline phases
AU2002951833A0 (en) *	2002-10-02	2002-10-24	Novogen Research Pty Ltd	Compositions and therapeutic methods invloving platinum complexes
TWI323662B (en) *	2002-11-15	2010-04-21	Telik Inc	Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE10256182A1 (de) *	2002-12-02	2004-06-24	Merck Patent Gmbh	2-Oxadiazolchromonderivate
DE502004006542D1 (de) *	2003-04-30	2008-04-30	Merck Patent Gmbh	Chromenonderivate
US20050020556A1 (en) *	2003-05-30	2005-01-27	Kosan Biosciences, Inc.	Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
WO2005111024A1 (en) *	2004-05-14	2005-11-24	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510963A (pt) *	2004-05-14	2007-11-20	Pfizer Prod Inc	derivados pirimidina para o tratamento do crescimento anormal de células
TW200538149A (en) *	2004-05-20	2005-12-01	Telik Inc	Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
TW200600091A (en) *	2004-05-21	2006-01-01	Telik Inc	Sulfonylethyl phosphorodiamidates
US7378423B2 (en) *	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
WO2006002119A2 (en) *	2004-06-18	2006-01-05	Gpc Biotech, Inc.	Kinase inhibitors for treating cancers
US20060003950A1 (en) *	2004-06-30	2006-01-05	Bone Care International, Inc.	Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
KR20070046183A (ko) *	2004-09-22	2007-05-02	화이자 인코포레이티드	폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는치료 배합물
US20090065522A1 (en) *	2004-10-13	2009-03-12	Nadir Benouali	Unit dose compliance monitoring and reporting device and system
US7807662B2 (en) *	2004-12-23	2010-10-05	University Of South Florida	Platinum IV complex inhibitor
US20090047365A1 (en) *	2005-02-28	2009-02-19	Eisai R & D Management Co., Ltd.	Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
US8106033B2 (en) *	2005-03-11	2012-01-31	Temple University - Of The Commonwealth System Of Higher Education	Composition and methods for the treatment of proliferative diseases
KR101509440B1 (ko) *	2005-05-12	2015-04-07	애브비 바하마스 리미티드	아폽토시스 촉진제
ES2719093T3 (es) *	2005-08-31	2019-07-08	Abraxis Bioscience Llc	Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación
US20070190180A1 (en) *	2005-11-08	2007-08-16	Pilkiewicz Frank G	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2007056264A2 (en) *	2005-11-08	2007-05-18	Transave, Inc.	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) *	2005-11-08	2007-08-16	Pilkiewicz Frank G	Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
WO2007064658A2 (en) *	2005-11-30	2007-06-07	Transave, Inc.	Safe and effective methods of administering therapeutic agents
US8143236B2 (en) *	2005-12-13	2012-03-27	Bionumerik Pharmaceuticals, Inc.	Chemoprotective methods
ES2444695T3 (es) *	2006-06-23	2014-02-26	Alethia Biotherapeutics Inc.	Polinucleótidos y polipéptidos implicados en el cáncer
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
CA2677639A1 (en) *	2007-02-09	2008-08-14	Poniard Pharmaceuticals, Inc.	Encapsulated picoplatin
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
CA2702305C (en) *	2007-03-30	2015-07-21	Bind Biosciences, Inc.	Cancer cell targeting using nanoparticles
WO2008150506A1 (en) *	2007-05-31	2008-12-11	Ascenta Therapeutics, Inc.	Pulsatile dosing of gossypol for treatment of disease
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20110053879A1 (en) *	2008-02-08	2011-03-03	Poniard Pharmaceuticals, Inc.	Picoplatin and amrubicin to treat lung cancer

2000
- 2000-05-18 GB GBGB0011903.2A patent/GB0011903D0/en not_active Ceased
2001
- 2001-05-09 MY MYPI20012142A patent/MY138923A/en unknown
- 2001-05-10 KR KR1020027015404A patent/KR20030014228A/ko not_active Ceased
- 2001-05-10 CN CNA200810110276XA patent/CN101310719A/zh active Pending
- 2001-05-10 WO PCT/GB2001/002060 patent/WO2001087313A1/en active IP Right Grant
- 2001-05-10 EE EEP200200648A patent/EE05261B1/xx not_active IP Right Cessation
- 2001-05-10 PL PL01357721A patent/PL357721A1/xx not_active IP Right Cessation
- 2001-05-10 US US10/276,503 patent/US20040053882A1/en not_active Abandoned
- 2001-05-10 NZ NZ521632A patent/NZ521632A/en not_active IP Right Cessation
- 2001-05-10 KR KR1020097006728A patent/KR20090040926A/ko not_active Ceased
- 2001-05-10 AU AU2001252442A patent/AU2001252442B8/en not_active Ceased
- 2001-05-10 AR ARP010102214A patent/AR030281A1/es unknown
- 2001-05-10 MX MXPA02011247A patent/MXPA02011247A/es active IP Right Grant
- 2001-05-10 EP EP01925764A patent/EP1283712A1/en not_active Ceased
- 2001-05-10 AU AU5244201A patent/AU5244201A/xx active Pending
- 2001-05-10 SK SK1639-2002A patent/SK16392002A3/sk not_active Application Discontinuation
- 2001-05-10 CN CNA2007101119747A patent/CN101084886A/zh active Pending
- 2001-05-10 CN CNB01809337XA patent/CN100411628C/zh not_active Expired - Fee Related
- 2001-05-10 IL IL15195901A patent/IL151959A0/xx unknown
- 2001-05-10 JP JP2001583780A patent/JP2003533485A/ja active Pending
- 2001-05-10 CZ CZ20023766A patent/CZ20023766A3/cs unknown
- 2001-05-10 EP EP04078357A patent/EP1530969A1/en not_active Ceased
- 2001-05-10 BR BR0110837-9A patent/BR0110837A/pt not_active Application Discontinuation
- 2001-05-10 HU HU0302130A patent/HUP0302130A3/hu unknown
- 2001-05-10 CA CA002410067A patent/CA2410067A1/en not_active Abandoned
- 2001-05-21 TW TW095125500A patent/TW200637565A/zh unknown
- 2001-10-05 UA UA20021210043A patent/UA81098C2/uk unknown
2002
- 2002-09-27 IS IS6571A patent/IS6571A/is unknown
- 2002-11-14 ZA ZA200209279A patent/ZA200209279B/en unknown
- 2002-11-15 BG BG107281A patent/BG66113B1/bg unknown
- 2002-11-15 NO NO20025502A patent/NO332079B1/no not_active IP Right Cessation
2003
- 2003-03-05 HK HK03101630.1A patent/HK1049446A1/zh unknown
2006
- 2006-03-09 AU AU2006201008A patent/AU2006201008C1/en not_active Ceased
- 2006-06-22 RU RU2006122350/15A patent/RU2429838C2/ru not_active IP Right Cessation
2010
- 2010-05-04 RU RU2010117635/15A patent/RU2587013C2/ru not_active IP Right Cessation
2011
- 2011-12-26 JP JP2011283923A patent/JP2012062329A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN100411628C (zh)	2008-08-20
CZ20023766A3 (cs)	2003-03-12
HK1049446A1 (zh)	2003-05-16
JP2012062329A (ja)	2012-03-29
IL151959A0 (en)	2003-04-10
UA81098C2 (uk)	2007-12-10
BG66113B1 (bg)	2011-05-31
EE200200648A (et)	2004-06-15
KR20090040926A (ko)	2009-04-27
RU2587013C2 (ru)	2016-06-10
PL357721A1 (en)	2004-07-26
EP1283712A1 (en)	2003-02-19
BG107281A (bg)	2003-09-30
SK16392002A3 (sk)	2003-04-01
EP1530969A1 (en)	2005-05-18
GB0011903D0 (en)	2000-07-05
KR20030014228A (ko)	2003-02-15
AU2006201008C1 (en)	2009-08-13
NO20025502D0 (no)	2002-11-15
AR030281A1 (es)	2003-08-20
NO20025502L (no)	2002-11-15
IS6571A (is)	2002-09-27
HUP0302130A3 (en)	2005-06-28
CN1429114A (zh)	2003-07-09
CA2410067A1 (en)	2001-11-22
AU2006201008A1 (en)	2006-04-06
JP2003533485A (ja)	2003-11-11
NO332079B1 (no)	2012-06-18
CN101084886A (zh)	2007-12-12
EE05261B1 (et)	2010-02-15
CN101310719A (zh)	2008-11-26
AU2001252442B8 (en)	2006-05-04
WO2001087313A1 (en)	2001-11-22
HUP0302130A2 (hu)	2003-11-28
NZ521632A (en)	2004-08-27
RU2429838C2 (ru)	2011-09-27
AU2001252442B2 (en)	2006-03-23
AU2006201008B2 (en)	2009-01-08
AU5244201A (en)	2001-11-26
US20040053882A1 (en)	2004-03-18
MY138923A (en)	2009-08-28
BR0110837A (pt)	2003-03-11
RU2010117635A (ru)	2011-11-10
RU2006122350A (ru)	2008-01-10
MXPA02011247A (es)	2004-08-19
ZA200209279B (en)	2004-02-16

Publication	Publication Date	Title
TW200637565A (en)	2006-11-01	Use of a sterically hindered platium coordination compound in combination with a non-platium based anti-cancer agent
Caravita et al.	2006	Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
AU4451101A (en)	2001-10-30	Method and compositions for preventing hormone induced adverse effects
TW200510375A (en)	2005-03-16	New compounds
AP1760A (en)	2007-07-18	Platinum derivative pharmaceutical formulations.
MXPA05013642A (es)	2006-03-10	Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
AU2003266322A1 (en)	2004-03-19	Lipid-polymer-conjugates compositions comprising corticosteroids for the treatment of cancer
AU4258101A (en)	2001-10-15	Combination therapies with vascular damaging activity
MXPA04010392A (es)	2005-08-18	Composiciones de cromo y metodos para utilizar las mismas para inhibir resistencia a insulina inducida por droga.
PL352756A1 (en)	2003-09-08	A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
WO2005016264A3 (en)	2005-11-17	Diamine derivatives of quinone and uses thereof
HK1082663A1 (en)	2006-06-16	Extract with anti-tumor and anti-poisonous activity
MX9800407A (es)	1998-04-30	Nuevos derivados de galantamina, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contiene.
TR200001147T2 (tr)	2000-08-21	Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
WO2001034174A3 (en)	2002-09-12	Methods for administration of therapeutic agents on an antiangiogenic schedule
HUP0300576A2 (hu)	2003-07-28	Érkárosító hatású, osztott dózisú gyógyászati készítmény
ZA200605900B (en)	2008-02-27	Glycosylated steroid derivatives with anti-migratory activity
HK1085744A1 (en)	2006-09-01	Steroid compounds with anti-tumor activity
MX2007007015A (es)	2007-07-04	Composiciones farmaceuticas para el tratamiento de celulitis.
MXPA05010135A (es)	2005-11-16	Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos.
HUP0001441A2 (hu)	2000-10-28	Eljárás 4-aza-androszt-1-én származékokat tartalmazó gyógyszerkészítmények előállítására
Blanke et al.	2001	A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies
Ishmael et al.	2003	Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors
SancheZ et al.	2008	The novel proteasome inhibitor CEP-18770 inhibits myeloma tumor growth in vitro and in vivo and enhances the anti-MM effects of melphalan
WO2000025727A3 (en)	2000-09-28	Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours